Envoy Medical Q2 revenue $68k, cash $1.7M; Acclaim CI pivotal trial goal by end-2024

Envoy Medical, Inc.

Revenue $68k (Q2 2024) vs $63k prior year; revenue from two Esteem units offset by battery sales decline.
R&D expenses rose $438k to $2.6M due to increased headcount for Acclaim CI pivotal study preparation.
Three EFS participants completed 18-month follow-up; all show CIQOL improvement, no SADEs/UADEs reported.
System noise mitigations implemented; two participants used hearing aid with Acclaim for better SNR.
Company maintains goal to submit IDE in coming months and start pivotal trial by year-end 2024; commercialization targeted by end-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.